10x Genomics, Inc. TXG Share-Based Payment Award Options Outstanding - Number
Share-Based Payment Award Options Outstanding - Number at other companies
Other financials
Where this comes from
Reported directly by 10x Genomics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.
The official record: 10x Genomics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about 10x Genomics, Inc.'s share-based payment award options outstanding - number.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 10x Genomics, Inc.'s share-based payment award options outstanding - number?
- 10x Genomics, Inc. (TXG) reported share-based payment award options outstanding - number of 3.4M in Q1 2026.
- How has 10x Genomics, Inc.'s share-based payment award options outstanding - number changed year-over-year?
- 10x Genomics, Inc.'s share-based payment award options outstanding - number decreased by 18.9% year-over-year, from 4.2M to 3.4M.
- What is the long-term trend for 10x Genomics, Inc.'s share-based payment award options outstanding - number?
- Over 5 years (2020 to 2025), 10x Genomics, Inc.'s share-based payment award options outstanding - number has grown at a -21.4% compound annual growth rate (CAGR), from 11.9M to 3.6M.
- What does share-based payment award options outstanding - number mean?
- This is the total count of stock options granted to employees and directors that remain unexercised at the reporting date. It reflects the total volume of potential equity claims currently held by the workforce. This metric is a key component in calculating fully diluted share counts.